Initial public offer of upto 62,53,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Q-Line Biotech Limited ("the Company" or "QLBL" or "the Issuer") at an issue price of Rs. 343 per equity share (including share premium of Rs. 333 per equity share) for cash, aggregating up to Rs. 214.48 Crores ("Public Issue") out of which 3,13,200 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating Rs. 10.74 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 59,40,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating upto Rs. 203.74 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.81% and 25.46% respectively of the post- issue paid-up equity share capital of the company.
The company, in consultation with the book running lead managers, may consider a pre-ipo placement of up to 8,00,000 equity shares for cash consideration ("pre-ipo placement") prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the book running lead managers. If the pre-ipo placement is undertaken, the number of equity shares issued pursuant to the pre-ipo placement shall be reduced from the issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended ("scrr").
Price Band: Rs. 343 per equity share of face value Rs. 10/- each.
The floor price (Rs.343) is 34.3 times of the face value of the equity shares.
Bids can be made for a minimum of 800 equity shares and in multiples of 400 equity shares thereafter.